|
 |
Article Review/Hyperlink
|
Teruel JL, Marcen R, Navarro-Antolin J, Aquilera A, Fernandez
-Juarez G, Ortuno J
Androgen versus erythropoeitin for the treatment of
anemia in hemodialyzed patients: a prospective study
J Am Soc Nephrol
(Jan) 7:140-144 1996

Prior to the introduction into clinical practice of recombinant
human erythropoietin (rHuEPO), androgen therapy was occasionally used in the
treatment of the anemia of end-stage renal disease. The anabolic effects of
androgens lead to an increase in red cell mass. Previous studies have
yielded
inconsistent results regarding the efficacy of this therapy.These authors
have previously observed androgens to be safe and effective in older men.
The
purpose of the current study was to compare androgens to rHuEPO in the
therapy of anemia in ESRD. Eighteen men selected on the basis of being more
that 50 years old were treated
with nandrolone decoanate (200 mg IM/week) for 6 months. Twenty-two men less
than 50 years old and women were treated with rHuEPO with dose titrated to
achieve a
hemoglobin level of 10-11 g/dl. Both groups had significant increases in
hemoglobin; androgen group from 7.3+/- 0.8 to 10.8 +/- 1.7, rHuEPO group from
7.0 +/-0.6 to 10.4 +/- 1.0. There was no statistically significant difference
between the responses in the two
groups. Hypertensive control worsened in the rHuEPO group in 45% of
patients,
compared to 6% in the androgen group. Patients in the androgen group had
significant increases in serum albumin, dry weight, and serum triglyceride
levels.
Comment: This is an interesting example of the current interest in
finding
less expensive alternatives to rHuEPO therapy. The authors have shown in a
small group of patients that androgens were as effective in older men, as
rHuEPO was in women and younger men. An obvious concern with this study
design is that the populations studied were different. Ideally, a randomized
approach, in which men greater than 50 years old received either androgens or
rHuEPO
would have provided a more satisfying answer to the research question.
Nonetheless, we should not discount the importance of these findings. If
older men were known to have a greater erythropoietic response than women or
young men, then the results of this study would be vitiated. There is no
known difference in reponse, therefore, I believe the study results are
probably valid. Confirmation in a larger trial, using a randomized study
design would be helpful. The anabolic effects of androgens would probably be
beneficial in older hemodialysis patients, and the increase in triglycerides
should not be clinically important. (Steven Fishbane MD, Winthrop-
University
Hospital, Mineola, NY)
Related Folders: |
 |
|
|
|
|